pemvidutide’s potential reshapes obesity and NASH stock outlook By Investing.com
Altimmune, Inc. (NASDAQ:), a clinical-stage biopharmaceutical company, has been making waves in the obesity and liver disease treatment landscape with its lead candidate, pemvidutide. As the company progresses through clinical trials and prepares for crucial data releases, investors and analysts are closely watching its potential to disrupt the market.
A Promising Contender in Obesity and NASH Treatment
Pemvidutide, Altimmune’s GLP/glucagon dual agonist, has shown encouraging results in clinical trials for both obesity and non-alcoholic steatohepatitis (NASH). The drug’s unique mechanism of action has garnered attention for its potential to offer benefits beyond weight loss, including favorable changes in body composition and lipid…
